University of Kentucky

UKnowledge
Psychology Faculty Publications

Psychology

10-2017

High Trait Shame Undermines the Protective Effects of
Prevalence Knowledge on State Shame Following HPV/CIN
Diagnosis in Women
Sarah McQueary Flynn
University of the Cumberlands

Tory A. Eisenlohr-Moul
University of North Carolina at Chapel Hill

Suzanne C. Segerstrom
University of Kentucky, segerstrom@uky.edu

Christen T. Logue
University of the Cumberlands

Jamie L. Studts
University of Kentucky, jamie.studts@uky.edu

Follow this and additional works at: https://uknowledge.uky.edu/psychology_facpub
Part of the Behavioral Medicine Commons, and the Psychology Commons

Right click to open a feedback form in a new tab to let us know how this document benefits you.
Repository Citation
Flynn, Sarah McQueary; Eisenlohr-Moul, Tory A.; Segerstrom, Suzanne C.; Logue, Christen T.; and Studts,
Jamie L., "High Trait Shame Undermines the Protective Effects of Prevalence Knowledge on State Shame
Following HPV/CIN Diagnosis in Women" (2017). Psychology Faculty Publications. 183.
https://uknowledge.uky.edu/psychology_facpub/183

This Article is brought to you for free and open access by the Psychology at UKnowledge. It has been accepted for
inclusion in Psychology Faculty Publications by an authorized administrator of UKnowledge. For more information,
please contact UKnowledge@lsv.uky.edu.

High Trait Shame Undermines the Protective Effects of Prevalence Knowledge on
State Shame Following HPV/CIN Diagnosis in Women
Digital Object Identifier (DOI)
https://doi.org/10.1007/s10865-017-9849-8

Notes/Citation Information
Published in Journal of Behavioral Medicine, v. 40, issue 5, p. 814-820.
© Springer Science+Business Media New York 2017
The copyright holder has granted the permission for posting the article here.
This is a post-peer-review, pre-copyedit version of an article published in Journal of Behavioral Medicine.
The final authenticated version is available online at: https://doi.org/10.1007/s10865-017-9849-8.

This article is available at UKnowledge: https://uknowledge.uky.edu/psychology_facpub/183

HHS Public Access
Author manuscript
Author Manuscript

J Behav Med. Author manuscript; available in PMC 2017 December 01.
Published in final edited form as:
J Behav Med. 2017 October ; 40(5): 814–820. doi:10.1007/s10865-017-9849-8.

High trait shame undermines the protective effects of prevalence
knowledge on state shame following HPV/CIN diagnosis in
women
Sarah McQueary Flynn1, Tory A. Eisenlohr-Moul2, Suzanne C. Segerstrom3, Christen T.
Logue1, and Jamie L. Studts3

Author Manuscript

1Program

in Clinical Psychology, University of the Cumberlands, 410 Meijer Drive, Florence, KY
41042, USA

2University

of North Carolina at Chapel Hill, Chapel Hill, NC, USA

3University

of Kentucky, Lexington, KY, USA

Abstract
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Human papillomavirus (HPV), and the related, cervical intraepithelial neoplasia (CIN), are
common yet poorly understood physical conditions. The diagnosis of HPV often elicits shame and
guilt, which in turn may undermine psychological and physical health. The current study
compared shame and guilt responses to diagnosis among two groups: women diagnosed with
HPV/CIN and women diagnosed with Epstein–Barr Virus (EBV/IM). Eighty women recently
diagnosed with HPV/CIN or EBV/IM completed measures of shame- and guilt-proneness, shame
and guilt following diagnosis, and disease knowledge including prevalence estimates (HPV and
EBV, respectively). HPV/CIN (vs. EBV/IM) predicted more diagnosis-related shame and guilt.
Estimates of high prevalence interacted with diagnosis and shame-proneness to predict diagnosisrelated shame. Simple slope analyses indicated that in women with HPV/CIN reporting low-toaverage shame-proneness, high prevalence estimates reduced diagnosis-related shame; however,
women high in shame-proneness experienced high diagnosis-related shame regardless of more
accurate prevalence estimates. Women high in shame-proneness appear to be particularly
vulnerable to HPV-related shame even when they are aware that it is very common.
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Introduction
Human papillomavirus (HPV), a sexually transmitted virus associated with cervical cancer
(Bosch & Muñoz, 2002), remains common despite recent vaccine development (Daley et al.,
2010). In fact, the Centers for Disease Control and Prevention (CDC) has recently reported
that HPV is so ubiquitous that nearly 100% of sexually active men and women will contract
it in their lifetime (CDC, 2017). A systematic review found that university students had
particularly high prevalence rates of approximately 20–40% (Revzina & DiClemente, 2005);
other data show that rates are approximately 45% for women ages 20–24 in the general
population, with prevalence increasing with each year of age until age 59 (Dunne et al.,
2007).

Author Manuscript

The HPV virus is usually suppressed by the immune system, preventing the development of
cervical intraepithelial neoplasia (CIN) or cervical cancer (Bollen et al., 1999). When the
immune system is not able to clear the infection, routine screenings and outpatient
treatments reduce cancer risk to negligible levels. Despite the high prevalence and
manageability of HPV, diagnosis is often accompanied by significant emotional disruption,
with a majority of individuals, particularly women, reporting feelings of shame (Daley et al.,
2010, 2015; Maissi et al., 2004). Not only do individuals with HPV experience shame after
learning about their diagnosis—they continue to feel shame for months to years afterward
(Clarke et al., 1996).

Author Manuscript

Diagnosis with HPV may cause shame because it represents a social threat; the diagnosis
may threaten feelings of social acceptance by evoking expectations of judgment by friends
or family for having a sexually-transmitted infection or by evoking expectations of potential
rejection by current or future sexual or romantic partners. Such social threats are robustly
linked to negative self-evaluative emotions such as shame, a broad, negative appraisal of the
self as bad or tarnished, as well as guilt, a negative evaluation of one’s behavior in a specific
situation (Tangney et al., 2007; Taylor, 1985). In contrast to diagnosis with HPV, diagnosis
with Epstein–Barr Virus (EBV/IM), a similarly common, communicable, and persistent
virus, is not associated with significant social threat, stigma, or associated feelings of shame
(Straus et al., 1993).
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Unfortunately, diagnosis-related shame may contribute to poorer psychological and physical
health outcomes in women with HPV, including risk for psychological disorders like anxiety
and depression (Dost & Yagmurlu, 2008; Kahn et al., 2007; Maissi et al., 2004; Orth et al.,
2006), poorer compliance with subsequent screening for cervical cancer (Miller et al., 1996),
and even disruption of the neuroendocrine and immune parameters involved in controlling
the infection (Dickerson et al., 2004; Gruenewald et al., 2004; Segerstrom et al., 1996).
Because diagnosis-related experiences of social threat and shame may be detrimental to
mental and physical well-being, more work is needed to understand the contextual and
personality factors that predict experiences of shame following an HPV diagnosis. Such
work could facilitate the provision of additional support and ultimately better psychological
and physical health outcomes in women diagnosed with HPV.
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It is possible that individual differences in the experience of social threat and shame
following HPV diagnosis are influenced by both contextual and personality variables; two
such variables will be investigated in the present study. First, given the extremely high
prevalence rates, accurate prevalence estimates may be expected to reduce feelings of
shame. Women who are aware of the high prevalence of HPV may be less likely to interpret
their diagnosis as reflecting negatively on the self. Despite high rates of HPV, knowledge of
HPV prevalence, transmission, prevention, and etiology seems to be relatively low in the
general population (Baer et al., 2000; Kahn et al., 2007; Maissi et al., 2004; Tiro et al.,
2007), even after significant increases in HPV education associated with the release of the
HPV vaccine (Daley et al., 2010). Specifically, a large percentage of women still do not
know that HPV is extremely common or that HPV rarely leads to cancer with routine
outpatient treatment (Aerssens et al., 2008; O’Connor et al., 2014). Therefore, mistaken
beliefs about low prevalence, which may lead one to fear social rejection on the basis of a
sexually-transmitted, stigmatized diagnosis, may be one contextual factor driving
experiences of shame following diagnosis (Daley et al., 2010; Kahn et al., 2007; Maissi et
al., 2004).
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Second, personality may also play a role in predicting shame responses to diagnosis. Higher
levels of trait shame-proneness have been found to increase the intensity and chronicity of
negative emotional and physiological responses to social threats, and may therefore predict
greater experiences of shame associated with HPV diagnosis regardless of prevalence beliefs
(Dickerson et al., 2004, 2008; Gruenewald et al., 2004). Further, it is also possible that
shame-proneness and inaccurate beliefs that prevalence is low interact to predict shame
responses to diagnosis. Because higher baseline feelings of social threat among some
individuals (i.e., shame-proneness, loneliness) are associated with poorer cognitive
functioning in socially stressful situations (Cacioppo & Hawkley, 2009) individuals with
high shame-proneness may be less able to use knowledge about high HPV prevalence to
buffer against diagnosis-related shame. Despite preliminary evidence suggesting that these
contextual and personality factors might play a role in HPV-related shame, no studies have
examined their interactive impact.

Author Manuscript

Therefore, the primary aim of the current study is to examine the interactive effects of
shame-proneness and low prevalence estimates (i.e., a lack of awareness that HPV is
common) on diagnosis-related shame and guilt in female college students recently diagnosed
with either HPV related cervical intraepithelial neoplasia (HPV/CIN) or infectious
mononucleosis (IM; caused by exposure to the Epstein–Barr Virus or EBV/IM). EBV/IM is
a comparable infection in regards to prevalence and immunosuppression, yet there is much
less social stigma associated with EBV/IM diagnosis than is associated with HPV/CIN
making it an ideal comparison group.
Hypotheses
Hypothesis 1—The primary prediction was that women with HPV/CIN will experience
significantly more post-diagnosis feelings of state shame and guilt than women diagnosed
with EBV/IM, but that trait levels of guilt- and shame-proneness will not differ between
diagnoses.
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Hypothesis 2—It was predicted that higher diagnostic prevalence estimates (of HPV/CIN
or EBV/IM, depending on the group) would be associated with lower state shame in
HPV/CIN patients but that no such relationship would exist in EBV/IM patients. That is,
individuals with HPV/CIN (vs. EBV/IM) who believe their diagnosis is more common will
have lower shame. Further, we hypothesized a two-way interaction between trait shameproneness and prevalence estimates predicting state shame such that only individuals low in
trait shame-proneness will be buffered against shame by believing that their disease is more
prevalent, whereas individuals with high trait shame-proneness will exhibit high shame
regardless of prevalence estimates.

Methods
Participants and Procedure

Author Manuscript

Eighty female college students (ages 18–28), 40 of whom were recently diagnosed with an
abnormal pap smear (i.e., cytology result) indicating HPV/CIN (test group) and 40 female
students in the same age range recently diagnosed with EBV/IM (comparison group), were
recruited to participate in a cross-sectional study via informational flyer (i.e., selfnomination) following appointments at a university health service clinic at a large
southeastern university or surrounding OB/GYN clinics. Participants were diagnosed with
HPV/CIN on the basis of abnormal cytology result. Individuals diagnosed with EBV/IM
were diagnosed on the basis of EBV antibodies on a blood test indicating recent infection.
Participation took place between initial diagnosis and any follow-appointments (e.g.,
colposcopy). Participants completed measures of shame, guilt, depression and distress in a
private room. In addition to those measures, participants completed a knowledge
questionnaire specific to their diagnosis which included an item that asked them to provide
an estimate of diagnosis prevalence. All participants received treatment as usual in the
context of the university health service or surrounding clinics prior to and following
participation. Power calculations based on previous work indicated that this number of
participants led to greater than 80% power to detect the medium-sized predicted effects. The
protocol was approved by the local institutional review board.

Author Manuscript

Measures
Demographic characteristics—Demographics were measured with questions inquiring
about age, race, income, and relationship status.
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Trait guilt and shame-proneness—The Guilt and Shame Proneness Scale (GASP) is a
20 item measure with two subscales measuring guilt-proneness as negative behaviorevaluations (present sample α = .54) and approach responses following private behaviors
(present sample α = .83) and two subscales measuring shame-proneness as negative selfevaluations (present sample α = .69) and avoidance responses following public behaviors
(present sample α = .78). Guilt subscales were collapsed to yield a total guilt-proneness
score, raising the reliability estimate to an acceptable level (present sample α = .81), (M =
5.31, SD = 1.03) (Cohen et al., 2011). Examples of items from the GASP include, “You
secretly commit a felony. What is the likelihood that you would feel remorse about breaking
the law?” and “You take office supplies home for personal use and you are caught by your

J Behav Med. Author manuscript; available in PMC 2017 December 01.

Flynn et al.

Page 5

Author Manuscript

boss. What is the likelihood that you would replace what you broke?” Each item is measured
on a scale of 1 (very unlikely) to 7 (very likely).
State (diagnosis-related) shame and guilt—The shame and guilt subscales of the
State Shame and Guilt Scale (SGSS) were also included (Gruenewald et al., 2004). This
measure was developed to assess state emotions and does not rely on respondent’s ability to
distinguish between the words ‘shame’ and ‘guilt.’ Items that measure shame include a
component of the global self such as: “I feel worthless, powerless.” Guilt items include a
behavioral component such as: “I feel bad about something that I have done.” Each item is
measured on a scale from 1 (not feeling this way at all) to 5 (feeling this way very strongly).
Participants were instructed to rate their feelings in response to their recent diagnosis of
HPV/CIN or EBV/IM.
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Prevalence estimates—Participants were asked, “Approximately what percentage of
individuals will contract (HPV or EBV/IM) in their lifetime?” and instructed to write a
percentage in the blank. Participants were not given information about true prevalence
estimates in the population. Estimated prevalence rates were nearly identical for both HPV
(M = 59.62%, SD = 18.54%) and EBV/IM (M = 59.21%, SD = 18.77%).
Statistical Analyses

Author Manuscript

All analyses were carried out using SPSS Statistics. To test Hypothesis 1, we used
independent t-tests to compare outcomes (state shame and guilt, trait shame and guilt)
between the two diagnostic groups. To test Hypothesis 2, we utilized a hierarchical linear
regression model predicting state shame from the following predictors: (1) samplestandardized trait shame proneness (SP), dichotomous diagnostic group (where EBV = 0 and
HPV = 1), and sample-standardized prevalence estimate for one’s diagnosis, (2) the
interactions of SP × group, SP × prevalence estimate, and group × prevalence estimate, and
(3) the three way interaction of SP × group × prevalence estimate. Significant three-way
interactions were probed by testing the two-way interaction of SP × prevalence estimate in
each diagnostic group. Significant two-way interactions within each diagnostic group were
further probed by testing the simple slope of prevalence estimate on the outcome at one SD
above and below the sample mean of trait shame-proneness.

Results
Demographic Information
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The average age of the participants was 21.39 years (SD = 2.95). Participants were
Caucasian (81%), African American (10%), and Hispanic (7%). There were no differences
between the diagnoses for race (χ2 (1, N = 80) = .24, p = .62), relationship status (χ2 (3, N
= 80) = 4.01, p = .26), education level (χ2 (4, N = 80) = 2.08, p = .72), income, (t(76) =
−1.73, p = .09), or age (t(78) = .42, p = .68). Due to immediate checking procedures, there
was no missing data in the present study—all participants completed all measures.
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Testing Hypothesis 1—Following diagnosis, HPV/CIN will be associated with greater
state shame and guilt than EBV/IM, but will not be associated with greater trait guilt-or
shame-proneness.
As predicted, women diagnosed with HPV/CIN (M = 2.94, SD = 0.97) had substantially
higher state shame scores than women diagnosed with EBV/IM (M = 1.80, SD = 0.60), t(78)
= 6.34, p < .001, d = 1.14, 95% CI for Mean Difference: .48 to 1.40. Similarly, women with
HPV/CIN (M = 2.08, SD = 1.00) had higher state guilt scores than women with EBV/IM (M
= 1.57, SD = .92), t(78) = 2.40), p = .02, d = 0.53, 95% CI for Mean Difference: .08 to .94.
These results were also consistent across subscales (all p’s < .05, all d’s > 0.2). Also as
predicted, the two groups did not differ in either the negative evaluation or avoidance scales
measuring shame-proneness (t(78) = −1.26, p = .21 and t(78) = 0.02, p = .98) or the total
scale measuring guilt-proneness (t(78) = .01, p = .99) (all d’s < 0.2).
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Testing Hypothesis 2—Among women with HPV/CIN, but not EBV/IM, more accurate
(i.e., higher) prevalence estimates will predict lower state shame following diagnosis and this
relationship between knowledge and state shame will be stronger among women low in trait
shame-proneness.
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Hierarchical linear regression analyses tested the three-way interaction of trait shameproneness, disease prevalence estimate, and HPV/CIN diagnosis on state shame following
diagnosis. We predicted that trait shame-proneness would moderate the effects of disease
prevalence estimates and diagnosis on state shame. The results of the interaction test can be
found in Table 1 and are depicted in Fig. 1. As predicted, the three way interaction was
significant such that (1) the two-way interaction between trait shame-proneness and
prevalence estimate was significant only among women with HPV/CIN, and (2) within
women with HPV/CIN, the association between higher prevalence estimates and lower state
shame following diagnosis was significant only among women low in trait shame-proneness
(simple slope of prevalence estimate on state shame among women with HPV/CIN with
lower-than-average shame-proneness: β = −.63, p = .005)—whereas women high in trait
shame-proneness who believed their diagnosis was prevalent were not buffered against state
shame following HPV/CIN diagnosis (simple slope of prevalence estimate on state shame
among women with HPV/CIN with higher-than-average shame-proneness: β = .16, p = .48).
Examination of leverage values indicated that these findings were not driven by multivariate
outliers.

Discussion
Author Manuscript

A diagnosis of HPV can lead to persistent experiences of distress, most notably shame and
guilt (Kahn et al., 2007; Maissi et al., 2004; Tangney et al., 2007). The current study found
that state shame and guilt—but not trait guilt-or shame-proneness—were higher in
HPV/CIN than in EBV/IM following diagnosis. Further, accurate estimates of disease
prevalence were not associated with state shame in women with EBV/IM, regardless of trait
levels of shame-proneness. However, among women diagnosed with HPV/CIN, estimates
that HPV/CIN was more prevalent were associated with decreased state shame following
diagnosis—but only among women low in trait shame-proneness.
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Given the present finding that HPV/CIN specifically predicts acute shame responses in a
treatment-as-usual framework, and given the evidence that such shame may persist and
increase risk for depression (Clarke et al., 1996), changes in clinical practice may be needed
to prevent negative consequences among women diagnosed with HPV. The present study
suggests that simply knowing that HPV is highly prevalent buffers against diagnosis-related
shame for many women. Unfortunately, HPV-related prevalence knowledge remains low in
the general population (Wong & Sam, 2010), and health care providers continue to give
incomplete or unclear information to their patients regarding HPV (Cermak et al., 2010). It
seems important for health care providers to clearly state that HPV is an extremely common
diagnosis, affecting the majority of women in order to reduce shame responses and
associated risk for depressive symptoms.
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Among women with HPV who are high in shame-proneness, however, education regarding
the prevalence of the diagnosis may not be effective (see Fig. 1). Women high in shameproneness who have an accurate understanding of HPV prevalence rates appear to be unable
to effectively use this knowledge of high prevalence to downregulate shame. One possibility
is that these women’s elevated levels of shame create a ceiling effect in which shame is
chronically elevated. Another possibility is that shame-prone women suffer from cognitive
interference due to the social threat of diagnosis and are therefore less able to make use of
the knowledge that HPV is extremely prevalent to reduce shame (Cacioppo & Hawkley,
2009). Finally, these women may not benefit from their own awareness of the high
prevalence of HPV because they realize that the general population is unaware of the high
prevalence of HPV, and may therefore react to an HPV diagnosis as shameful despite its
high prevalence. It may be advisable to refer these women for more comprehensive
psychosocial interventions such as cognitive behavioral strategies in order to effectively
downregulate shame and associated risk for psychological distress.
Strengths and Weaknesses of the Present Study
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The present study has several strengths. Inclusion of a comparison group of women
diagnosed with another immunologically similar disease (EBV/IM) allows the current study
to demonstrate that shame is common in response to diagnosis with HPV/CIN specifically.
This was the first study of its kind to use this type of clinical control condition. Additionally,
group differences in negative affective responses to diagnosis were not due to individual
differences in shame- and guilt-proneness, suggesting that there is something unique about
the experience of being diagnosed with HPV/CIN that elicits this negative self-directed
affect. Finally, some previous research has asked individuals to imagine that they were
diagnosed with HPV, whereas the current study adds to the small body of literature using
actual HPV/CIN patients to provide clearer support for the HPV-shame link.
The present study is not without limitations. First, the present study does not allow for
specific conclusions regarding the specificity of shame responding to HPV/CIN diagnoses as
compared to other sexually-transmitted infections. Rather, it allows only for a comparison
between HPV/CIN and EBV/IM, a non-sexually-transmitted infection. Second, the roles of
perceived disease severity and treatability, which may overlap substantially with perceptions
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of disease prevalence, were not examined in the present study. It may be that beliefs
regarding the treatability or severity of HPV/CIN play an important role in the link between
perceptions of low disease prevalence and shame responding, and future studies should
examine these possibilities. Third, due to the cross-sectional nature of the study, it is
unknown whether immediate reactions to diagnosis would remain stable over time. Lastly,
participants were not further prompted to give more information regarding diagnosis
prevalence rates and did not receive additional information about actual diagnosis prevalence
rates in the general or university population. Therefore, it is unknown whether the
prevalence estimates that participants provided were merely a best guess or a truly accurate
measure of participant’s knowledge of diagnosis prevalence.

Future Considerations and Conclusions
Author Manuscript
Author Manuscript

Future work should further examine the predictors and consequences of shame responses to
HPV diagnosis. One particularly interesting possibility is that prolonged experiences of
shame and guilt could influence disease prognosis in women diagnosed with HPV, both
through behavioral outcomes such as failing to follow through with subsequent cervical
cancer screenings, as well as through detrimental stress-related neuroendocrine and immune
responses. Shame has been shown to be associated with increases in cortisol activity
(Gruenewald et al., 2004) and proinflammatory cytokine activity (Dickerson et al., 2004)
under social threat. Moreover, negative self-evaluative emotions such as shame specifically
cause declines in CD4+ T helper cells in HIV over the long term (Dickerson et al., 2004;
Segerstrom et al., 1996). Therefore, persistent shame experiences in HPV patients may very
well be associated with declines in key immune parameters vital to clearance of HPV
cervical lesions (Coleman et al., 1994). This further highlights the importance of
interventions that target shame.
In conclusion, this study demonstrates that, compared with EBV/IM, HPV/CIN diagnosis is
related to greater acute shame and guilt. In addition, knowledge that HPV is very common
protects against acute shame following diagnosis; however, this may only be true for women
with low-to-average levels of trait shame. Therefore, further research is warranted to further
clarify these processes and to identify effective methods for downregulating shame among
women diagnosed with HPV.
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Fig. 1.

Depiction of the three-way interaction between trait shame-proneness, diagnosis prevalence
beliefs, and HPV/CIN (vs. EBV/IM) diagnosis predicting state shame
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